Antibody-Negative Stiff Person Syndrome Non-Responder After Hematopoietic Cell Transplant

Stiff person syndrome (SPS) is an uncommon immune-mediated disease characterized by muscle stiffness, spasms, and rigidity. Approximately 65% of cases are antibody-positive with multiple reported antibody targets, including glutamic acid decarboxylase (GAD65), the α1-subunit of the glycine receptor, amphiphysin, gephyrin, dipeptidyl peptidase-like protein 6 (DPPX), and the γ-aminobutyric acid-A receptor (GABAaR). ¹ SPS can be refractory to conventional immunosuppression. Autologous hematopoietic cell transplantation (HCT) has been reported as a treatment option in refractory autoantibody-positive cases. ^2–4 Herein we describe a case of antibody-negative SPS with no improvement after HCT.

A middle-aged man with type 1 diabetes presented in March 2018 with constant stiffness in his low back. Over the next year, the stiffness spread up his trunk and into his neck, legs, and arms with superimposed painful spasms that were triggered spontaneously and at times by unexpected motion such as bumps on the road while driving. Symptoms progressed to the point where he was unable to work. Initial testing included normal magnetic resonance imaging of the whole spine and negative testing for glutamic acid decarboxylase 65 (GAD65; radioimmunoassay), anti-gamma-aminobutyric acid (GABAaR; cell-based assay), ampiphysin (cell-based assay), and DPPX (immunofluorescence assay) through Mayo Clinic Laboratories in both serum and cerebrospinal fluid (CSF). CSF studies showed elevated protein at 0.67 g/l (normal <= 0.4 g/L) but were otherwise normal including absent oligoclonal bands. Anti-nuclear antibodies were positive in a speckled pattern at a high titer (1:640). Diazepam had initially been helpful, but its use was limited by side effects; trials of baclofen, tizanidine, and dantrolene showed minimal benefit.

He continued to be followed in the neuromuscular clinic. Exam in December 2019 was remarkable for increased paraspinal muscle tone and axial and lower limb rigidity without exaggerated startle response or hyperlordosis. He had a characteristic stiff-legged “tin man” gait. Nerve conduction studies and needle electromyography (EMG) revealed continuous paraspinal muscle activity as well as agonist and antagonist co-contraction with patellar reflex. Repeat GAD65 testing done locally (sandwich immunoassay, DynaLife Labs) was initially borderline positive in the serum (5.1 IU/ml, normal <= 5.0 IU/ml) but was negative when repeated. Serum anti-glycine antibodies were negative (cell-based assay, Oxford Neuroimmunology Laboratory). Whole-body positron emission tomography (PET) was negative for malignancy but did show a significant increase in metabolic activity in axial/limb muscles (Fig. 1), as previously described in SPS. ⁵

Figure 1. Whole-body ¹⁸F-FDG PET scan showing generalized increased uptake within the musculature, most evident within the forearms, thighs, and calves (a.) with a normal scan for comparison (b.).

His symptoms continued to worsen despite a two-month trial of intravenous immunoglobulin (2 g/kg induction and monthly 1 g/kg maintenance). Rituximab (1000mg for 2 doses, 2 weeks apart) was subsequently given without improvement in symptoms. A course of pulsed high-dose oral prednisone (1250 mg) for 5 days was followed by maintenance daily prednisone (1 mg/kg), which was discontinued due to side effects. He then continued weekly pulsed oral prednisone (1250mg) for 1 month then biweekly for 2 months with only a slight reduction of stiffness and spasms. Plasmapheresis (5 exchanges over 10 days) was also ineffective. Multiple symptomatic therapies including levetiracetam, gabapentin, pregabalin, vigabatrin, and valproic acid had minimal benefit.

Due to refractory severe symptoms, we proceeded with autologous HCT in September 2020 using the Ottawa protocol for multiple sclerosis (using high doses of busulfan and cyclophosphamide and rabbit antithymocyte globulin followed by infusion of autologous CD34⁺ cells). ⁶ Peri-transplant complications included pulmonary embolism, neutropenic fever, presumed proctitis, and cytomegalovirus reactivation. With therapy, these complications resolved.

Monthly neurological reassessment occurred for 13 months after HCT. He reported ongoing progression of stiffness/spasms and has developed progressive neuropathic pain in his legs responsive to diazepam as well as a new diagnosis of bilateral adhesive capsulitis. His exam continued to demonstrate axial and lower extremity rigidity and a new lumbar hyperlordosis. Sensory exam has remained normal. Repeat electrophysiology demonstrated continued agonist-antagonist co-contraction.

This report illustrates a case of SPS refractory to HCT. It is the first antibody-negative patient to undergo HCT in the literature. Despite the lack of antibody positivity, we felt confident in the diagnosis of SPS given the clear findings on exam, EMG, and PET scan. Nonetheless, diagnosis of antibody-negative SPS remains challenging given that the specificity of both clinical findings and para-clinical tests such as EMG and PET are unknown. ⁷

More data are needed to determine whether autoantibody-negative SPS is a contraindication to HCT. A limitation of this report is the lack of pretransplant antibody testing for gephyrin.

A recent clinical trial of HCT in GAD65-positive SPS suggested lack of efficacy in certain sub-populations of patients including those with negative GAD65 antibodies in CSF. ⁶ There are however other clinical characteristics that may predict poor response such as rigidity on examination, and EMG-documented simultaneous contraction of agonist-antagonist limb muscles, both of which were seen in this case. While some patients with SPS clearly improve with HCT, this case demonstrates that HCT may not be effective for all forms of refractory SPS.